124 related articles for article (PubMed ID: 1381907)
1. An O-linked carbohydrate neutralization epitope of HIV-1 gp 120 is expressed by HIV-1 env gene recombinant vaccinia virus.
Hansen JE; Clausen H; Hu SL; Nielsen JO; Olofsson S
Arch Virol; 1992; 126(1-4):11-20. PubMed ID: 1381907
[TBL] [Abstract][Full Text] [Related]
2. Identification of three N-linked glycans in the V4-V5 region of HIV-1 gp 120, dispensable for CD4-binding and fusion activity of gp 120.
Hemming A; Bolmstedt A; Jansson B; Hansen JE; Travis B; Hu SL; Olofsson S
Arch Virol; 1994; 134(3-4):335-44. PubMed ID: 8129620
[TBL] [Abstract][Full Text] [Related]
3. Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region.
Losman B; Bolmstedt A; Schønning K; Björndal A ; Westin C; Fenyö EM; Olofsson S
AIDS Res Hum Retroviruses; 2001 Jul; 17(11):1067-76. PubMed ID: 11485624
[TBL] [Abstract][Full Text] [Related]
4. The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.
Pinter A; Honnen WJ; D'Agostino P; Gorny MK; Zolla-Pazner S; Kayman SC
J Virol; 2005 Jun; 79(11):6909-17. PubMed ID: 15890930
[TBL] [Abstract][Full Text] [Related]
5. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity of HIV-1 to neutralization by antibodies against O-linked carbohydrate epitopes despite deletion of O-glycosylation signals in the V3 loop.
Hansen JE; Jansson B; Gram GJ; Clausen H; Nielsen JO; Olofsson S
Arch Virol; 1996; 141(2):291-300. PubMed ID: 8634021
[TBL] [Abstract][Full Text] [Related]
7. Mapping of the human immunodeficiency virus type 2 envelope glycoprotein CD4 binding region and fusion domain with truncated proteins expressed by recombinant vaccinia viruses.
Otteken A; Voss G; Hunsmann G
Virology; 1993 May; 194(1):37-43. PubMed ID: 8480426
[TBL] [Abstract][Full Text] [Related]
8. Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.
Martín J; LaBranche CC; González-Scarano F
J Virol; 2001 Apr; 75(8):3568-80. PubMed ID: 11264346
[TBL] [Abstract][Full Text] [Related]
9. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
[TBL] [Abstract][Full Text] [Related]
10. Carbohydrate determinant NeuAc-Gal beta (1-4) of N-linked glycans modulates the antigenic activity of human immunodeficiency virus type 1 glycoprotein gp120.
Bolmstedt A; Olofsson S; Sjögren-Jansson E; Jeansson S; Sjöblom I; Akerblom L; Hansen JE; Hu SL
J Gen Virol; 1992 Dec; 73 ( Pt 12)():3099-105. PubMed ID: 1281869
[TBL] [Abstract][Full Text] [Related]
11. Antibodies to several conformation-dependent epitopes of gp120/gp41 inhibit CCR-5-dependent cell-to-cell fusion mediated by the native envelope glycoprotein of a primary macrophage-tropic HIV-1 isolate.
Verrier FC; Charneau P; Altmeyer R; Laurent S; Borman AM; Girard M
Proc Natl Acad Sci U S A; 1997 Aug; 94(17):9326-31. PubMed ID: 9256481
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies raised against covalently crosslinked complexes of human immunodeficiency virus type 1 gp120 and CD4 receptor identify a novel complex-dependent epitope on gp 120.
DeVico AL; Rahman R; Welch J; Crowley R; Lusso P; Sarngadharan MG; Pal R
Virology; 1995 Aug; 211(2):583-8. PubMed ID: 7544051
[TBL] [Abstract][Full Text] [Related]
13. Simplified procedure for fractionation and structural characterisation of complex mixtures of N-linked glycans, released from HIV-1 gp120 and other highly glycosylated viral proteins.
Biller M; Bolmstedt A; Hemming A; Olofsson S
J Virol Methods; 1998 Dec; 76(1-2):87-100. PubMed ID: 9923743
[TBL] [Abstract][Full Text] [Related]
14. Purified complexes of HIV-1 envelope glycoproteins with CD4 and CCR5(CXCR4): production, characterization and immunogenicity.
Xiao X; Phogat S; Shu Y; Phogat A; Chow YH; Wei OL; Goldstein H; Broder CC; Dimitrov DS
Vaccine; 2003 Oct; 21(27-30):4275-84. PubMed ID: 14505910
[TBL] [Abstract][Full Text] [Related]
15. Rapid selection for an N-linked oligosaccharide by monoclonal antibodies directed against the V3 loop of human immunodeficiency virus type 1.
Schønning K; Jansson B; Olofsson S; Hansen JE
J Gen Virol; 1996 Apr; 77 ( Pt 4)():753-8. PubMed ID: 8627264
[TBL] [Abstract][Full Text] [Related]
16. Stable expression of the transfected HIV-1 env gene in a human B cell line: characterization of gp120-expressing clones and immunobiological studies.
Ahmad A; Ladha A; Cohen EA; Menezes J
Virology; 1993 Feb; 192(2):447-57. PubMed ID: 8421893
[TBL] [Abstract][Full Text] [Related]
17. Chimeric viruses expressing primary envelope glycoproteins of human immunodeficiency virus type I show increased sensitivity to neutralization by human sera.
McKeating JA; Zhang YJ; Arnold C; Frederiksson R; Fenyö EM; Balfe P
Virology; 1996 Jun; 220(2):450-60. PubMed ID: 8661395
[TBL] [Abstract][Full Text] [Related]
18. Murine monoclonal antibodies biologically active against the amino region of HIV-1 gp120: isolation and characterization.
Dickey C; Ziegner U; Agadjanyan MG; Srikantan V; Refaeli Y; Prabhu A; Sato A; Williams WV; Weiner DB; Ugen KE
DNA Cell Biol; 2000 Apr; 19(4):243-52. PubMed ID: 10798448
[TBL] [Abstract][Full Text] [Related]
19. Conserved N-linked oligosaccharides of the C-terminal portion of human immunodeficiency virus type 1 gp120 and viral susceptibility to neutralizing antibodies.
Hemming A; Gram GJ; Bolmstedt A; Losman B; Hansen JE; Ricksten A; Olofsson S
Arch Virol; 1996; 141(11):2139-51. PubMed ID: 8973529
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of recombinant Modified Vaccinia Ankara Viruses (rMVA) expressing HIV-1 Indian subtype C gag-protease and env-gp120 genes in mice.
Kumar S; Seth P
Viral Immunol; 2004; 17(4):574-9. PubMed ID: 15671754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
